ESG

As Uxin prepares to report Q3 results, all eyes are on its ambitious superstore strategy and whether it can drive profitability in a complex market.

Genmab's $8 billion acquisition of Merus isn't just a deal; it's a bold strategy to own its destiny and dominate the future of oncology therapeutics.

SEALSQ appoints public-private partnership veteran Rolf Gobet to lead its new Geneva Quantum Center, a key move in a well-funded race against quantum threats.

A new startup is betting a premium AI desktop calendar can cure our smartphone addiction. But is another screen really the answer to too much screen time?

A South Korean firm has solved a hidden flaw in industrial magnets, promising a leap in efficiency for battery, recycling, and mining industries.

A new 'inspired by' fragrance brand is betting its vertically integrated model and aggressive pricing can break the industry’s century-old luxury spell.

Health Union's new platform for ATTR amyloidosis isn't just a website. It's a strategic blend of patient support and business innovation. Here's why.

Serina Therapeutics poaches a top chemist to expand its POZ platform, signaling a major push beyond Parkinson's into new, high-value drug markets.

Dialed Moods' new sea moss and shilajit gummies enter a booming market. But do the ancient ingredients and modern science justify the industry's latest rush?

Zoetis boosts its dividend by 6%, but what does this move signal about the company's financial health and the booming global animal care market?

Tenaya Therapeutics unveils promising interim data for its ARVC gene therapy, TN-401, hinting at a potential cure and igniting investor interest.

BrightView Holdings declared its eighth straight cash dividend, a move signaling financial discipline even as it navigates revenue challenges and stock volatility.

Tenaya Therapeutics seeks fresh capital to advance its heart disease pipeline, but the offering's structure raises dilution questions for investors.

Dynex's routine dividend declaration reveals a complex strategy of risk management and capital allocation, offering a masterclass in navigating mREIT turbulence.

A routine filing reveals a major strategic play. See how BridgeBio Oncology uses special equity grants to attract top minds in the fierce race for a cancer cure.

Argan's repeated dividend hikes and record backlog reflect deep confidence, positioning it to capitalize on surging demand for critical energy infrastructure.

Beyond a new logo, WaterFurnace's rebranding reveals a major strategic shift to dominate commercial markets, fueled by policy tailwinds and surging demand.

Tevogen CEO's $100k stock gift to local police offers a case study in ESG, community engagement, and the strategic value of corporate social responsibility.

A 150-year-old agricultural giant is pivoting its strategy, using a sophisticated data model to link sustainability directly to its bottom line.

With a new CEO, Menagerie Cellars is doubling down on its blend of luxury wine and conservation. Can this purpose-driven model scale in a tough market?